Print page

Competition Law And Patents

A Follow-on Innovation Perspective in the Biopharmaceutical Industry
New Horizons in Competition Law and Economics series
Irina Haracoglou, Attorney at Law, Independent Researcher/Consultant
Using the example of research tools in biopharmaceutical research and innovation, this book examines the complexities of the relationship between two fundamental areas of law and policy – intellectual property rights and competition law. It addresses a question that is certain to become paramount in other industries also: how to strike the balance between initial and follow-on innovation so as to ensure that access to ‘essential’ research tools (or other fundamental elements to follow-on innovation) is not impeded. The book concludes by suggesting how competition law could be used to complement the patent balance.
Extent: 272 pp
Hardback Price: £83.00 Online: £74.70
Publication Date: 2008
ISBN: 978 1 84720 599 5
Availability: In Stock
£0.00

Buy the E-book

Join our mailing list

  • Economics and Finance
  • Competition Policy
  • Law - Academic
  • Biotechnology and Pharmaceutical Law
  • Competition and Antitrust Law
  • Intellectual Property Law
Using the example of research tools in biopharmaceutical research and innovation, this book examines the complexities of the relationship between two fundamental areas of law and policy – intellectual property rights and competition law. It addresses a question that is certain to become paramount in other industries also: how to strike the balance between initial and follow-on innovation so as to ensure that access to ‘essential’ research tools (or other fundamental elements to follow-on innovation) is not impeded. The book concludes by suggesting how competition law could be used to complement the patent balance.

Competition Law and Patents caters for various groups ranging from those with a general interest in competition law, patent law and/or biopharmaceuticals, to students who want to understand how competition and intellectual property work in practice (or to understand the interface between the two policies), and from practitioners and policymakers to people within the biopharmaceutical industry itself.
‘This is an original and well-argued thesis overall, of particular interest to policy makers and academics in both IP and competition law.’
– Ioannis Lianos, World Competition

‘This is an incredibly interesting book on an increasingly pertinent topic. . . the book is succinctly written and provides a comprehensive overview of EU law. . . providing a really useful analysis of the European cases concerned with the imposition of a duty to deal in relation to intellectual property. . . This book is a thoroughly enjoyable read, and perhaps because of its brevity the author retains her focus on the central issues being examined. I found it to be engaging and thought provoking.’
– Jane Nielsen, Competition and Consumer Law Journal

‘The book caters for various groups ranging from those with a general interest in competition law, patent law and/or biopharmaceuticals, to students who want to understand how competition and intellectual property work in practice (or to understand the interface between the two policies), and from practitioners and policymakers to people within the biopharmaceutical industry itself.’
– Journal of Intellectual Property Rights
Contents: Preface Part I: The Problem – Access as a Necessary Element of Follow-on Innovation? 1. Biopharmaceutical R&D: The Increased Importance of Cumulative Innovation and Related Concerns Part II: The Patent Balance and Working Solutions in the Patent System 2. The Patent System as a System of Balancing 3. The Patent System and Some Potential Safety Nets 4. The Right to Health as an Interpretive Principle of Patent Law Part III: Antitrust as a Complement to the Patent System 5. Unilateral Conduct, Intellectual Property Rights and Competition Law: A Systems’ Interaction 6. The Duty to Deal under Art. 82 EC Part IV: A More Innovation Sensitive Approach to the Interface of Competition Law and Patents? 7. The Duty to Deal as Applied to Address Technology Access Problems in the Biopharmaceutical Industry Bibliography Index